Results 11 to 20 of about 39,225 (199)
Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
Cells, 2022 Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin.
Natalya Maluchenko +4 more
doaj +3 more sources
Mechanisms of Nucleosome Reorganization by PARP1 [PDF]
International Journal of Molecular Sciences, 2021 Poly(ADP-ribose) polymerase 1 (PARP1) is an enzyme involved in DNA repair, chromatin organization and transcription. During transcription initiation, PARP1 interacts with gene promoters where it binds to nucleosomes, replaces linker histone H1 and participates in gene regulation.
Natalya V. Maluchenko +10 more
openaire +2 more sources
The Nucleolus and PARP1 in Cancer Biology [PDF]
Cancers, 2020 The nucleolus has been known for a long time to fulfill crucial functions in ribosome biogenesis, of which cancer cells can become addicted to in order to produce sufficient amounts of proteins for cell proliferation. Recently, the nucleolus has emerged as a central regulatory hub in many other cancer-relevant processes, including stress sensing, DNA ...
Engbrecht, Marina, Mangerich, Aswin
openaire +3 more sources
Pyridazine Based Compounds with PARP-1 Inhibitory Activity
Archives of Pharmaceutical Sciences Ain Shams University, 2023 Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman +3 more
doaj +1 more source
iScience, 2023 Summary: PARP1 contributes to genome architecture and DNA damage repair through its dynamic association with chromatin. PARP1 and PARP2 (PARP1/2) recognize damaged DNA and recruit the DNA repair machinery.
Jyothi Mahadevan +6 more
doaj +1 more source
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation [PDF]
Nature Chemical Biology, 2019 PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders.
Shuai Wang +8 more
openaire +2 more sources
Folia Neuropathologica, 2020 Trauma is the main cause of death for people aged 1-45, and among them, traumatic brain injury (TBI) is the major condition, which causes over 50,000 deaths each year and costs over 80 billion per year.
Yiqiang Cao +4 more
doaj +1 more source
Trial watch: STING agonists in cancer therapy
OncoImmunology, 2020 Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors, most of which sense ectopic DNA ...
Julie Le Naour +4 more
doaj +1 more source
Molecules, 2023 The protein PARP1, which plays a crucial role in DNA repair processes, is an attractive target for cancer therapy, especially for BRCA-deficient cancers.
Fengqin Yan +3 more
doaj +1 more source
Poly(ADP-Ribose) Polymerase-1 Lacking Enzymatic Activity Is Not Compatible with Mouse Development
Cells, 2023 Poly(ADP-ribose) polymerase-1 (PARP1) binds DNA lesions to catalyse poly(ADP-ribosyl)ation (PARylation) using NAD+ as a substrate. PARP1 plays multiple roles in cellular activities, including DNA repair, transcription, cell death, and chromatin ...
Tatiana Kamaletdinova +11 more
doaj +1 more source